Recently, the General Office of Shandong Provincial People's Government issued a document titled the Several Measures on Optimizing Review and Approval Services to Promote High-quality Development of the Pharmaceutical Industry, which encompasses 20 policy measures spanning seven aspects.

The province will accelerate the high-quality development of its pharmaceutical industry through an array of initiatives. These include supporting the innovative research and development of pharmaceuticals, improving inspection and testing services, enhancing the review and verification service system, advancing product promotion and application, and fortifying the establishment of standards and building of brand reputation.

Shandong is determined to develop a top-tier inspection and testing platform that leads domestically while achieving world-class standards. To improve the inspection and testing service capability, the province has outlined within the 20 policy measures a plan to transform the platform for provincial food, drug, and medical device innovation and supervision services into an inspection, testing, and industrial development service institution characterized by substantial scale, complete qualifications, and robust expertise.

Shandong encourages pharmaceutical companies, especially those newly established, reconstructed, and expanded enterprises to promote intelligent manufacturing and research and develop inspection guidelines for intelligent manufacturing. The province will take measures to intensify the regulation of high-end new medical devices such as proton therapy systems. These actions are expected to establish the province as a benchmark for the regulation of high-end new medical devices throughout China.